Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA

INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA GENE THERAPY SOBOL, R. E., Fakhrai, H., Shawler, D., GJERSET, R., Dorigo, O., Carson, C., KHALEGHI, T., KOZIOL, J., Shiftan, T. A., Royston, I. 1995; 2 (2): 164-167

Abstract

A patient with glioblastoma multiforme (GBM) who had failed conventional therapy was treated with IL-2 gene therapy. The patient received 10 subcutaneous immunizations with autologous tumor cells and fibroblasts genetically modified to secrete IL-2 by retroviral gene transfer. An antitumor immune response mediated in part by CD8+ cytotoxic T cells was demonstrated with the patient's peripheral blood mononuclear cells. A magnetic resonance imaging (MRI) scan performed 4 weeks after the highest treatment dose revealed marked tumor necrosis. These results support the evaluation of this form of IL-2 gene therapy in additional patients with glioblastoma.

View details for Web of Science ID A1995QK78200012

View details for PubMedID 7719933